• 1
    Hench P S, Kendall E C, Slocumb Ch, Polley H F. The effect of a hormone of the adrenal cortex and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin 1949: 24: 181193.
  • 2
    Maibach H I, Wester R C. Issues in measuring percutaneous absorption of topical corticosteroids. Int J Dermatol 1992: 31 (Suppl. 1): 2125.
  • 3
    Robertson D B, Maibach H I. Adverse systemic effects of topical corticoids. In: MaibachH I, SurberC, eds. Topical Corticosteroids. Basel: Karger, 1992: 163169.
  • 4
    Sterry W, Asadullah K. Topical glucocorticoid therapy in dermatology. Ernst Schering Res Found Workshop 2002: 40: 3954.
  • 5
    Kao J S, Fluhr J W, Man M Q et al. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol 2003: 120: 456464.
  • 6
    Kimura T, Doi K. Dorsal skin reactions of hairless dogs to topical treatment with corticosteroids. Toxicol Pathol 1999: 27: 528535.
  • 7
    Booth B A, Tan E M, Oikarinen A, Uitto J. Steroid-induced dermal atrophy: effects of glucocorticosteroids on collagen metabolism in human skin fibroblast cultures. Int J Dermatol 1982: 21: 333337.
  • 8
    Mills C M, Marks R. Side effects of topical glucocorticoids. Curr Probl Dermatol 1993: 21: 122131.
  • 9
    Epstein N N, Epstein W L, Epstein J H. Atrophic striae in patients with inguinal intertrigo. Arch Dermatol 1963: 87: 450457.
  • 10
    Kolbe L, Kligman A M, Schreiner V, Stoudemayer T. Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin. Skin Res Technol 2001: 7: 7377.
  • 11
    Saarni H, Hopsu-Havu V K. The decrease of hyaluronate synthesis by anti-inflammatory steroids in vitro. Br J Dermatol 1978: 98: 445449.
  • 12
    Lehmann P, Zheng P, Lavker R M, Kligman A M. Corticosteroid atrophy in human skin. A study by light, scanning, and transmission electron microscopy. J Invest Dermatol 1983: 81: 169176.
  • 13
    Sheu H M, Lee J Y, Chai C Y, Kuo K W. Depletion of stratum corneum intercellular lipid lamellae and barrier function abnormalities after long-term topical corticosteroids. Br J Dermatol 1997: 136: 884890.
  • 14
    Scharffetter-Kochanek K, Krieg T. Adverse systemic effects of topical corticoids. In: Braun-FalcoO, PlewigG, WolffH H, BurgdorfW, LandthalerM, eds. Dermatologie und Venerologie. Berlin: Springer, 2005: 641715.
  • 15
    Röcken M, Ghoreschi K. Morphea and lichen sclerosus. In: BologniaJ L, LorizzoJ L, RapinR P, eds. Dermatology. Edinburgh: Mosby-Elsevier, 2003: 15031517.
  • 16
    Ebner H. Atrophien. In: Korting, G W, ed. Dermatologie in der Praxis und Klinik für die Fachärztliche Weiterbildung. Stuttgart: Thieme Verlag, 1979: pp. 34.6034.72.
  • 17
    Garbe C, Wolf G. Topische Therapie. In: Braun-FalcoO, PlewigG, WolffH H, BurgdorfW, LandthalerM, eds. Dermatologie und Venerologie. Berlin: Springer, 2005: 14311461.
  • 18
    Smith E W, Haigh J M, Surber C. Quantification of corticosteroid-induced skin vasoconstriction: visual ranking, chromameter measurement or digital imaging analysis. Dermatology 2002: 205: 310.
  • 19
    Cornell R C, Stoughton R B. The use of topical steroids in psoriasis. Dermatol Clin 1984: 2: 397408.
  • 20
    Stoughton R B, Cornell R C. Corticosteroids. In: FitzpatrickT B, EisenA J, WolffK, FreedbergI M, AustenK F, eds. Dermatology in General Medicine. New York: McGraw-Hill, 1993: 28462850.
  • 21
    Luger T, Loske K D, Elsner P et al. Topische Dermatotherapie mit Glukokortikoiden Therapeutischer Index. J Dtsch Dermatol Ges 2004: 2: 629634.
  • 22
    Schackert C, Korting H C, Schäfer-Korting M. Qualitative and quantitative assessment of the benefit-risk ratio of medium potency topical corticosteroids in vitro and in vivo: characterisation of drugs with an increased benefit-risk ratio. Biodrugs 2000: 13: 267277.
  • 23
    Schäfer-Korting M, Korting H C, Kerscher M J, Lenhard S. Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids. Clin Pharmacol Ther 1993: 54: 448456.
  • 24
    Korting H C, Kerscher M J, Schafer-Korting M. Topical glucocorticoids with improved benefit/risk ratio. do they exist? J Am Acad Dermatol 1992: 27: 8792.
  • 25
    Schurer N Y, Elias P M. The biochemistry and function of stratum corneum lipids. Adv Lipid Res 1991: 24: 2756.
  • 26
    Feingold K R, Man M Q, Menon G K, Cho S S, Brown B E, Elias P M. Cholesterol synthesis is required for cutaneous barrier function in mice. J Clin Invest 1990: 86: 17381745.
  • 27
    Elias P M, Brown B E. The mammalian cutaneous permeability barrier: defective barrier function is essential fatty acid deficiency correlates with abnormal intercellular lipid deposition. Lab Invest 1978: 39: 574583.
  • 28
    Delforno C, Holt P J, Marks R. Corticosteroid effect on epidermal cell size. Br J Dermatol 1978: 98: 619623.
  • 29
    Lange K, Kleuser B, Gysler A et al. Cutaneous inflammation and proliferation in vitro: differential effects and mode of action of topical glucocorticoids. Skin Pharmacol Appl Skin Physiol 2000: 13: 93103.
  • 30
    Marks R, Halprin K, Fukui K, Graff D. Topically applied triamcinolone and macromolecular synthesis by human epidermis. J Invest Dermatol 1971: 56: 470473.
  • 31
    Fischer L B, Maibach H I. The effect of corticosteroids on human epidermal mitotic activity. Arch Dermatol 1971: 103: 39.
  • 32
    Zendegui J G, Inman W H, Carpenter G. Modulation of the mitogenic response of an epidermal growth factor-dependent keratinocyte cell line by dexamethasone, insulin, and transforming growth factor-beta. J Cell Physiol 1988: 136: 257265.
  • 33
    Laurence E B, Christophers E. Selective action of hydrocortisone on postmitotic epidermal cells in vivo. J Invest Dermatol 1976: 66: 222229.
  • 34
    Woodbury R, Kligman A M. The hairless mouse model for assaying the atrophogenicity of topical corticosteroids. Acta Derm Venereol 1992: 72: 403406.
  • 35
    Sheu H M, Chang C H. Alterations in water content of the stratum corneum following long-term topical corticosteroids. J Formos Med Assoc 1991: 90: 664669.
  • 36
    Sheu H M, Tai C L, Kuo K W, Yu H S, Chai C Y. Modulation of epidermal terminal differentiation in patients after long-term topical corticosteroids. J Dermatol 1991: 18: 454464.
  • 37
    Sheu H M, Yu H S, Sheen T C. Histochemical and ultrastructural studies on cutaneous side effects due to topical corticosteroids. I. Changes in epidermis. Derm Sinica 1989: 7: 143153.
  • 38
    Hein R, Korting H C, Mehring T. Differential effect of medium potent nonhalogenated double-ester-type and conventional glucocorticoids on proliferation and chemotaxis of fibroblasts in vitro. Skin Pharmacol 1994: 7: 300306.
  • 39
    Ponec M, De Haas C, Bachra B N, Polano M K. Effects of glucocorticosteroids on primary human skin fibroblasts. I. Inhibition of the proliferation of cultured primary human skin and mouse L929 fibroblasts. Arch Dermatol Res 1977: 259: 117123.
  • 40
    Hammer S, Sauer B, Spika I, Schraut C, Kleuser B, Schafer-Korting M. Glucocorticoids mediate differential anti-apoptotic effects in human fibroblasts and keratinocytes via sphingosine-1-phosphate formation. J Cell Biochem 2004: 91: 840851.
  • 41
    Oakley R H, Cidlowski J A. The glucocorticoid receptor: expression, function, and regulation of glucocorticoid responsiveness. In: GouldingN J, FlowerR J, eds. Glucocorticoids. Basel: Birkhäuser, 2001: 5580.
  • 42
    Beato M, Chalepakis G, Schauer M, Slater E P. DNA regulatory elements for steroid hormones. J Steroid Biochem 1989: 32: 737747.
  • 43
    Lefstin J A, Yamamoto K R. Allosteric effects of DNA on transcriptional regulators. Nature 1998: 392: 885888.
  • 44
    Sakai D D, Helms S, Carlstedt-Duke J, Gustafsson J A, Rottman F M, Yamamoto K R. Hormone-mediated repression: a negative glucocorticoid response element from the bovine prolactin gene. Genes Dev 1988: 2: 11441154.
  • 45
    Stromstedt P E, Poellinger L, Gustafsson J A, Carlstedt-Duke J. The glucocorticoid receptor binds to a sequence overlapping the TATA box of the human osteocalcin promoter: a potential mechanism for negative regulation. Mol Cell Biol 1991: 11: 33793383.
  • 46
    De Bosscher K, Vanden Berghe W, Vermeulen L, Plaisance S, Boone E, Haegeman G. Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc Natl Acad Sci USA 2000: 97: 39193924.
  • 47
    Schüle R, Rangarajan P, Kliewer S et al. Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell 1990: 62: 12171226.
  • 48
    Tuckermann J P, Reichardt H M, Arribas R, Richter K H, Schutz G, Angel P. The DNA binding-independent function of the glucocorticoid receptor mediates repression of AP-1-dependent genes in skin. J Cell Biol 1999: 147: 13651370.
  • 49
    Cutroneo K R, Rokowski R, Counts D F. Glucocorticoids and collagen synthesis: comparison of in vivo and cell culture studies. Coll Relat Res 1981: 1: 557568.
  • 50
    Nuutinen P, Autio P, Hurskainen T, Oikarinen A. Glucocorticoid action on skin collagen. overview on clinical significance and consequences. J Eur Acad Dermatol Venereol 2001: 15: 361362.
  • 51
    Schäcke H, Docke W D, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002: 96: 2343.
  • 52
    Vuorio E, De Crombrugghe B. The family of collagen genes. Annu Rev Biochem 1990: 59: 837872.
  • 53
    Chu M L, De Wet W, Bernard M, Ramirez F. Fine structural analysis of the human pro-alpha: 1 (I): collagen gene. Promoter structure, AluI repeats, and polymorphic transcripts. J Biol Chem 1985: 260: 23152320.
  • 54
    Chen S J, Yuan W, Lo S, Trojanowska M, Varga J. Interaction of smad3 with a proximal smad-binding element of the human alpha2(I) procollagen gene promoter required for transcriptional activation by TGF-beta. J Cell Physiol 2000: 183: 381392.
  • 55
    Song C Z, Tian X, Gelehrter T D. Glucocorticoid receptor inhibits transforming growth factor-beta signaling by directly targeting the transcriptional activation function of Smad3. Proc Natl Acad Sci USA 1999: 96: 1177611781.
  • 56
    Meisler N, Shull S, Xie R et al. Glucocorticoids coordinately regulate type I collagen pro alpha 1 promoter activity through both the glucocorticoid and transforming growth factor beta response elements: a novel mechanism of glucocorticoid regulation of eukaryotic genes. J Cell Biochem 1995: 59: 376388.
  • 57
    Oishi Y, Fu Z W, Ohnuki Y, Kato H, Noguchi T. Molecular basis of the alteration in skin collagen metabolism in response to in vivo dexamethasone treatment. effects on the synthesis of collagen type I and III, collagenase, and tissue inhibitors of metalloproteinases. Br J Dermatol 2002: 147: 859868.
  • 58
    Shull S, Cutroneo K R. Glucocorticoids change the ratio of type III to type I procollagen extracellularly. Coll Relat Res 1986: 6: 295300.
  • 59
    Cutroneo K R, Stassen F L, Cardinale G J. Anti-inflammatory steroids and collagen metabolism: glucocorticoid-mediated decrease of prolyl hydroxylase. Mol Pharmacol 1975: 11: 4451.
  • 60
    Oikarinen A, Hannuksela M. Effect of hydrocortisone-17-butyrate, hydrocortisone, and clobetasol-17-propionate on prolyl hydroxylase activity in human skin. Arch Dermatol Res 1980: 267: 7982.
  • 61
    Kivirikko K I, Risteli L. Biosynthesis of collagen and its alterations in pathological states. Med Biol 1976: 54: 159186.
  • 62
    Ponec M, Hasper I, Vianden G D, Bachra B N. Effects of glucocorticosteroids on primary human skin fibroblasts. II. Effects on total protein and collagen biosynthesis by confluent cell cultures. Arch Dermatol Res 1977: 259: 125134.
  • 63
    Young J M, Yoxall B E, Wagner B M. Corticosteroid-induced dermal atrophy in the rat. J Invest Dermatol 1977: 69: 458462.
  • 64
    Oikarinen A, Autio P. New aspects of the mechanism of corticosteroid-induced dermal atrophy. Clin Exp Dermatol 1991: 16: 416419.
  • 65
    Vogel K G, Paulsson M, Heinegard D. Specific inhibition of type I and type II collagen fibrillogenesis by the small proteoglycan of tendon. Biochem J 1984: 223: 587597.
  • 66
    Kähäri V M, Hakkinen L, Westermarck J, Larjava H. Differential regulation of decorin and biglycan gene expression by dexamethasone and retinoic acid in cultured human skin fibroblasts. J Invest Dermatol 1995: 104: 503508.
  • 67
    Santra M, Danielson K G, Iozzo R V. Structural and functional characterization of the human decorin gene promoter. A homopurine-homopyrimidine S1 nuclease-sensitive region is involved in transcriptional control. J Biol Chem 1994: 269: 579587.
  • 68
    Del Monaco M, Covello S P, Kennedy S H, Gilinger G, Litwack G, Uitto J. Identification of novel glucocorticoid-response elements in human elastin promoter and demonstration of nucleotide sequence specificity of the receptor binding. J Invest Dermatol 1997: 108: 938942.
  • 69
    Russell S B, Trupin J S, Kennedy R Z, Russell J D, Davidson J M. Glucocorticoid regulation of elastin synthesis in human fibroblasts: down-regulation in fibroblasts from normal dermis but not from keloids. J Invest Dermatol 1995: 104: 241245.
  • 70
    Vincenti M P, White L A, Schroen D J, Benbow U, Brinckerhoff C E. Regulating expression of the gene for matrix metalloproteinase-1 (collagenase): mechanisms that control enzyme activity, transcription, and mRNA stability. Crit Rev Eukaryot Gene Expr 1996: 6: 391411.
  • 71
    Frisch S M, Ruley H E. Transcription from the stromelysin promoter is induced by interleukin-1 and repressed by dexamethasone. J Biol Chem 1987: 262: 1630016304.
  • 72
    Jonat C, Rahmsdorf H J, Park K K et al. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell 1990: 62: 11891204.
  • 73
    Sheu H M, Lee J Y, Kuo K W, Tsai J C. Permeability barrier abnormality of hairless mouse epidermis after topical corticosteroid: characterization of stratum corneum lipids by ruthenium tetroxide staining and high-performance thin-layer chromatography. J Dermatol 1998: 25: 281289.
  • 74
    Winter G D, Burton J L. Experimentally induced steroid atrophy in the domestic pig and man. Br J Dermatol 1976: 94 (Suppl. 12): 107109.
  • 75
    Hepburn D J, Aeling J L, Weston W L. A reappraisal of topical steroid potency. Pediatr Dermatol 1996: 13: 239245.
  • 76
    Vázquez-López F, Marghoob A A. Dermoscopic assessment of long-term topical therapies with potent steroids in chronic psoriasis. J Am Acad Dermatol 2004: 51: 811813.
  • 77
    Newton J A, Whitaker J, Sohail S, Young M M, Harding S M, Black M M. A comparison of pulsed ultrasound, radiography and micrometer screw gauge in the measurement of skin thickness. Curr Med Res Opin 1984: 9: 113118.
  • 78
    Marks R, Dykes PJ, Roberts E. The measurement of corticosteroid induced dermal atrophy by a radiological method. Arch Dermatol Res 1975: 253: 9396.
  • 79
    Niedner R. Animal models. In: MaibachH I, SurberC, eds. Topical Corticosteroids. Basel: Karger, 1992: 716.
  • 80
    Kirby J D, Munro D D. Steroid-induced atrophy in an animal and human model. Br J Dermatol 1976: 94 (Suppl. 12): 111119.
  • 81
    Schwartz E, Mezick J A, Gendimenico G J, Kligman L H. In vivo prevention of corticosteroid-induced skin atrophy by tretinoin in the hairless mouse is accompanied by modulation of collagen, glycosaminoglycans, and fibronectin. J Invest Dermatol 1994: 102: 241246.
  • 82
    Schäcke H, Schottelius A, Docke W D et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 2004: 101: 227232.
  • 83
    Smith J G Jr, Wehr R F, Chalker D K. Corticosteroid-induced cutaneous atrophy and telangiectasia. Experimental production associated with weight loss in rats. Arch Dermatol 1976: 112: 11151117.
  • 84
    Lavker R M, Dong G, Zheng P S, Murphy G F. Hairless micropig skin. A novel model for studies of cutaneous biology. Am J Pathol 1991: 138: 687697.
  • 85
    Winter G D, Wilson L. The effect of clobetasone butyrate and other topical steroids on skin thickness of the domestic pig. Br J Dermatol 1976: 94: 545550.
  • 86
    Castor C W, Baker B L. The local action of adrenocortical steroids on epidermis and connective tissue of the skin. Endocrinology 1950: 47: 234241.
  • 87
    Marks R. Methods for the assessment of skin atrophogenicity of topical corticosteroids. Dermatologica 1976: 152 (Suppl. 1): 117126.
  • 88
    Young J M, Yoxall B E, Wagner B M. Topical betamethasone 17-valerate is an anticorticosteroid in the rat. 1. Dermal atrophy. Br J Dermatol 1978: 99: 655663.
  • 89
    Child K J, English A F, Gilbert H G, Hewitt A, Woollett E A. Vasoconstrictor and systemic activities of topical steroids. Arch Dermatol 1968: 97: 407410.
  • 90
    Durant S, Duval D, Homo-Delarche F. Factors involved in the control of fibroblast proliferation by glucocorticoids: a review. Endocr Rev 1986: 7: 254269.
  • 91
    Görmar F E, Bernd A, Holzmann H. The effect of hydrocortisone aceponate on proliferation, total protein synthesis and collagen synthesis in human skin fibroblasts in vitro. Arzneimittelforschung 1990: 40: 192196.
  • 92
    Wach F, Bosserhoff A, Kurzidym U, Nowok K, Landthaler M, Hein R. Effects of mometasone furoate on human keratinocytes and fibroblasts in vitro. Skin Pharmacol Appl Skin Physiol 1998: 11: 4351.
  • 93
    Ponec M, De Haas C, Bachra B N, Polano M K. Effects of glucocorticosteroids on cultured human skin fibroblasts. III. Transient inhibition of cell proliferation in the early growth stages and reduced susceptibility in later growth stages. Arch Dermatol Res 1979: 265: 219227.
  • 94
    Bundesministerium für Verbraucherschutz, Ernährung und Landwirtschaft. Tierschutzbericht der Bundesregierung, 2005: 6970. Available at
  • 95
    Brazzini B, Pimpinelli N. New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use. Am J Clin Dermatol 2002: 3: 4758.
  • 96
    Nuutinen P, Riekki R, Parikka M et al. Modulation of collagen synthesis and mRNA by continuous and intermittent use of topical hydrocortisone in human skin. Br J Dermatol 2003: 148: 3945.
  • 97
    Mcmichael A J, Griffiths C E, Talwar H S et al. Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy. Br J Dermatol 1996: 135: 6064.
  • 98
    Frosch P J. Local corticoid treatment – possibilities and recommendations. Z Hautkr 1987: 62: 919924.
  • 99
    Du Vivier A, Phillips H, Hehir M. Applications of glucocorticosteroids. The effects of twice-daily vs once-every-other-day applications on mouse epidermal cell DNA synthesis. Arch Dermatol 1982: 118: 305308.
  • 100
    Fukaya Y, Masutani M, Koyama Y, Takahashi H, Ueda H. A study of systemic and topical effects of topical steroid application through the comparison of two application schedules. J Dermatol 1990: 17: 2833.
  • 101
    Korting H C, Hanifin J, Gupta A K, Rajagopalan R. Maintenance treatment and early intervention – the new paradigm in the management of atopic eczema. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. J Dtsch Dermatol Ges 2005: 3: 519523.
  • 102
    Hanifin J, Gupta A K, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002: 147: 528537.
  • 103
    Furue M, Terao H, Rikihisa W et al. Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. Br J Dermatol 2003: 148: 128133.
  • 104
    Prawer S E, Katz H I. Guidelines for using superpotent topical steroids. Am Fam Physician 1990: 41: 15311538.
  • 105
    Billich A, Aschauer H, Aszodi A, Stuetz A. Percutaneous absorption of drugs used in atopic eczema. pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm 2004: 269: 2935.
  • 106
    Billich A, Vyplel H, Grassberger M, Schmook F P, Steck A, Stuetz A. Novel cyclosporin derivatives featuring enhanced skin penetration despite increased molecular weight. Bioorg Med Chem 2005: 13: 31573167.
  • 107
    Korting H C, Unholzer A, Schafer-Korting M, Tausch I, Gassmueller J, Nietsch K H. Different skin thinning potential of equipotent medium-strength glucocorticoids. Skin Pharmacol Appl Skin Physiol 2002: 15: 8591.
  • 108
    Isogai M, Shimizu H, Esumi Y, Terasawa T, Okada T, Sugeno K. Binding affinities of mometasone furoate and related compounds including its metabolites for the glucocorticoid receptor of rat skin tissue. J Steroid Biochem Mol Biol 1993: 44: 141145.
  • 109
    Bonina F P, Puglia C, Barbuzzi T et al. In vitro and in vivo evaluation of polyoxyethylene esters as dermal prodrugs of ketoprofen, naproxen and diclofenac. Eur J Pharm Sci 2001: 14: 123134.
  • 110
    Brattsand R, Miller-Larsson A. The role of intracellular esterification in budesonide once-daily dosing and airway selectivity. Clin Ther 2003: 25 (Suppl. C): C28C41.
  • 111
    Lee H J, Cooperwood J S, You Z, Ko D H. Prodrug and antedrug: two diametrical approaches in designing safer drugs. Arch Pharm Res 2002: 25: 111136.
  • 112
    Gysler A, Lange K, Korting H C, Schafer-Korting M. Prednicarbate biotransformation in human foreskin keratinocytes and fibroblasts. Pharm Res 1997: 14: 793797.
  • 113
    Jordana M, Sarnstrand B, Sime P J, Ramis I. Immune-inflammatory functions of fibroblasts. Eur Respir J 1994: 7: 22122222.
  • 114
    Kessler-Becker D, Krieg T, Eckes B. Expression of pro-inflammatory markers by human dermal fibroblasts in a three-dimensional culture model is mediated by an autocrine interleukin-1 loop. Biochem J 2004: 379: 351358.
  • 115
    Levy J, Gassmuller J, Schroder G, Audring H, Sonnichsen N. Comparison of the effects of calcipotriol, prednicarbate and clobetasol 17-propionate on normal skin assessed by ultrasound measurement of skin thickness. Skin Pharmacol 1994: 7: 231236.
  • 116
    Fesq H, Lehmann J, Kontny A et al. Improved risk-benefit ratio for topical triamcinolone acetonide in Transfersome in comparison with equipotent cream and ointment: a randomized controlled trial. Br J Dermatol 2003: 149: 611619.
  • 117
    Korting H C, Zienicke H, Schafer-Korting M, Braun-Falco O. Liposome encapsulation improves efficacy of betamethasone dipropionate in atopic eczema but not in psoriasis vulgaris. Eur J Clin Pharmacol 1990: 39: 349351.
  • 118
    Santos Maia C, Mehnert W, Schaller M et al. Drug targeting by solid lipid nanoparticles for dermal use. J Drug Target 2002: 10: 489495.
  • 119
    Barnes P J. Cytokine-directed therapies for asthma. J Allergy Clin Immunol 2001: 108: S72S76.
  • 120
    Schäcke H, Hennekes H, Schottelius A et al. SEGRAs: a novel class of anti-inflammatory compounds. Ernst Schering Res Found Workshop 2002: 40: 357371.
  • 121
    Schäcke H, Rehwinkel H. Dissociated glucocorticoid receptor ligands. Curr Opin Invest Drugs 2004: 5: 524528.
  • 122
    Buttgereit F, Burmester G R, Lipworth B J. Optimised glucocorticoid therapy: the sharpening of an old spear. Lancet 2005: 365: 801803.
  • 123
    Maatta A, Penttinen R P. A fibroblast protein binds the 3′-untranslated region of pro-alpha 1(I) collagen mRNA. Biochem J 1993: 295 (Pt 3): 691698.
  • 124
    Russell S B, Trupin J S, Myers J C et al. Differential glucocorticoid regulation of collagen mRNAs in human dermal fibroblasts. Keloid-derived and fetal fibroblasts are refractory to down-regulation. J Biol Chem 1989: 264: 1373013735.
  • 125
    Oikarinen A, Salo T, Ala-Kokko L, Tryggvason K. Dexamethasone modulates the metabolism of type IV collagen and fibronectin in human basement-membrane-forming fibrosarcoma (HT-1080) cells. Biochem J 1987: 245: 235241.
  • 126
    Kähäri V M. Dexamethasone suppresses elastin gene expression in human skin fibroblasts in culture. Biochem Biophys Res Commun 1994: 201: 11891196.
  • 127
    Oikarinen A, Vuorio E, Vuorio T. Comparison of the effects of dexamethasone and 13-cis-retinoic acid on connective tissue biosynthesis in human skin fibroblasts. Arch Dermatol Res 1989: 281: 273278.
  • 128
    Zoppi N, Ghinelli A, Gardella R, Barlati S, Colombi M. Effect of dexamethasone on the assembly of the matrix of fibronectin and on its receptors organization in Ehlers – Danlos syndrome skin fibroblasts. Cell Biol Int 1998: 22: 499508.
  • 129
    Kylmaniemi M, Oikarinen A, Oikarinen K, Salo T. Effects of dexamethasone and cell proliferation on the expression of matrix metalloproteinases in human mucosal normal and malignant cells. J Dent Res 1996: 75: 919926.
  • 130
    Ekblom M, Fassler R, Tomasini-Johansson B, Nilsson K, Ekblom P. Downregulation of tenascin expression by glucocorticoids in bone marrow stromal cells and in fibroblasts. J Cell Biol 1993: 123: 10371045.
  • 131
    Spearman R I, Jarrett A. Bio-assay of corticosteroids for topical application. Br J Dermatol 1975: 92: 581584.
  • 132
    Weirich E G, Longauer J. Comparative animal experiments on epidermal hypoplasia induced by means of topical glucocorticoids. Z Hautkr 1974: 49: 91106.